CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients – News-Medical.net
News-Medical.net |
CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients
News-Medical.net In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a … Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma Phase 2 CAR–T study reports significant remission rates at 15-month follow up New Data for FDA-Approved CAR T Therapy Show Significant … |
